We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: NT-proBNP
MedXY News
EnglishTag

NT-proBNP

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Longitudinal Heart Stress Changes and Cardiovascular Risk in Older Adults: Insights from NT-proBNP Dynamics
Cardiologycardiovascular diseaseolder adults

Longitudinal Heart Stress Changes and Cardiovascular Risk in Older Adults: Insights from NT-proBNP Dynamics

By MedXY|Aug 20, 2026

Changes in NT-proBNP levels over three years define heart stress status, which improves cardiovascular and mortality risk prediction in older adults without prior CVD, underscoring its utility in clinical risk stratification.

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?
CardiologyCardiologygeriatrics
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?

By MedXY|Jan 18, 2026

A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-gui

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF
CardiologyHFpEFNT-proBNP

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY|Dec 26, 2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Cardiologyheart failurelifestyle intervention

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

By MedXY|Dec 26, 2025

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated o

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study
Cardiologycognitive impairmentDấu Hiệu Sinh Học Tim

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

By MedXY|Dec 25, 2025

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk f

Electromechanical Activation Time (EMAT) Links to Cardiac Dysfunction but Offers No Advantage Over NT‑proBNP for Community Screening
CardiologyNT-proBNP

Electromechanical Activation Time (EMAT) Links to Cardiac Dysfunction but Offers No Advantage Over NT‑proBNP for Community Screening

By MedXY|Nov 29, 2025

In a 3,401-participant community cohort, prolonged EMAT correlated with lower LVEF and worse outcomes but poorly discriminated reduced LVEF and provided no incremental prognostic information beyond NT‑proBNP.

Volenrelaxin in HFpEF: Unexpected Worsening of Congestion Despite Improvements in Left Atrial Function
Cardiologyheart failure with preserved ejection fractionNT-proBNP

Volenrelaxin in HFpEF: Unexpected Worsening of Congestion Despite Improvements in Left Atrial Function

By MedXY|Oct 6, 2025

This phase 2 trial shows that volenrelaxin, a long-acting relaxin analog, failed to improve overall congestion or kidney function in HFpEF patients and was linked to worsening congestion and safety signals, despite modest left atrial functi

NT-proBNP as a Prognostic Biomarker for Mortality in Ischemic Stroke: Insights from a Comprehensive Meta-Analysis
Cardiologyischemic strokemortality prediction

NT-proBNP as a Prognostic Biomarker for Mortality in Ischemic Stroke: Insights from a Comprehensive Meta-Analysis

By MedXY|Oct 4, 2025

This systematic review and meta-analysis evaluates NT-proBNP’s accuracy in predicting mortality among ischemic stroke patients, revealing moderate to high prognostic performance with potential clinical utility in risk stratification.

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial
Cardiologyaortic stenosisNT-proBNP

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY|Oct 3, 2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concent

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial
Cardiologyheart failureleft ventricular hypertrophy

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial

By MedXY|Oct 2, 2025

The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients wit

Dual Biomarker Strategy: Enhancing Prognosis in Acute Heart Failure with CA125 and NT-proBNP in Vietnam
Cardiologyacute heart failurebiomarkers

Dual Biomarker Strategy: Enhancing Prognosis in Acute Heart Failure with CA125 and NT-proBNP in Vietnam

By MedXY|Oct 2, 2025

Combining CA125 with NT-proBNP significantly improves prediction of cardiovascular and all-cause mortality, as well as rehospitalization risk in patients with acute heart failure.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities